Navigation Links
Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome

Torrance-based firm will introduce NutreStore(TM) in spring 2008

TORRANCE, Calif., Dec. 19 /PRNewswire/ -- Emmaus Medical, Inc., a Torrance, California based pharmaceutical company, announced today that it has entered into an exclusive sublicense agreement with Cato BioVentures of Research Triangle Park, North Carolina for the patent protected drug NutreStore(TM) brand L-Glutamine. Under this agreement, Emmaus will commercialize NutreStore(TM), which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome (SBS). Emmaus will be introducing NutreStore(TM) in the spring of 2008 and projects that its sales will greatly contribute to its short and long term financial performance of the company.

SBS is a serious and life threatening condition afflicting around 20,000 Americans who have lost large portions of their small intestine. This leads to a malnourished condition requiring total parenteral nutrition (TPN) through intravenous feeding.

NutreStore(TM) in conjunction with human growth hormone and an appropriate diet is the first new treatment since the development of TPN for patients with short bowel syndrome. Clinical studies of this combination therapy administered to SBS patients dependent upon TPN for nutritional support showed a significant reduction in the required weekly volume, caloric content and frequency of TPN administration compared to patients treated with human growth hormone alone. "This combination therapy offers patients a unique opportunity to improve intestinal absorption of food, which leads to a much better quality of life for SBS patients," said Douglas Wilmore, M.D., a board member of Emmaus. Dr. Wilmore is an Emeritus Frank Sawyer Professor of Surgery at Harvard Medical School, the inventor of this SBS treatment, and Editor-in-Chief of the Medscape General Surgery section of Medscape Today, at

Currently, patients who require L-Glutamine must purchase non-pharmaceutical grade L-Glutamine on their own without insurance coverage. With a prescription, NutreStore(TM) will be covered by insurance, thus lifting a large financial burden from patients who wish to optimize their SBS treatment with an FDA approved pharmaceutical product.

"Cato BioVentures is excited to partner with Emmaus Medical for the marketing of NutreStore(TM) and looks forward to a long and successful relationship with the company," said Joel Eisner, Ph.D., Associate Principal of Cato BioVentures.

About Emmaus Medical, Inc.

Emmaus Medical, Inc., led by Yutaka Niihara, M.D., M.P.H., CEO, and Daniel R. Kimbell, Esq., COO, is a private company founded to develop new treatments for sickle cell disease and other orphan diseases such as SBS. Emmaus works closely with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) and is currently conducting multi-center, double blind, placebo controlled, clinical trials to determine the safety and efficacy of L-Glutamine for sickle cell disease. Emmaus Medical is the recipient of an FDA orphan drug designation and fast track designation for the sickle cell project. For more information, please visit our website

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley. For more information, please visit our website


Henry Macan, M.D., Senior Manager

Emmaus Medical, Inc.

3870 Del Amo Boulevard, Unit 507

Torrance, CA 90503-7701

Tel. 310.214.0065


Joel Eisner, Ph.D., Associate Principal

Cato BioVentures

4364 South Alston Avenue

Durham, NC 27713

Tel. 919-361-2286


SOURCE Emmaus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
11. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
Post Your Comments:
(Date:11/30/2015)... ... , ... According to an article published November 13th by People ... to show her Instagram followers that the praise that they were bestowing on her ... she didn’t “want to mislead any mommy's who just had babies and are stressing,” ...
(Date:11/30/2015)... ... ... Cycling, running, and walking are regular Sunday activities for many South Floridians, ... 2016. , That’s when the 7th annual ANF Group Tour de Broward will ... families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored by ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one ... , Their study showed that small molecule analogs that target the functions of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar ... and adults, according to a new study by researchers at the School of Public ... and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public ...
(Date:11/30/2015)... Pittsburgh, PA (PRWEB) , ... November 30, 2015 ... ... according to a new study by UPMC and KingMed Diagnostics ... UPMC over three years found that consultation with UPMC pathologists resulted in significantly ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 Booth #4303 – The Imaging Components business ... a broader array of products in a new booth (#4303) ... North America in Chicago ... feature X-ray components "At the Heart of Imaging." Products will ... from Varian,s Claymount brand, and computer-aided diagnostic software from MeVis ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology: